Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

References

• Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50. doi:10.1038/nrc798.
   PubMed Web of Science ®Google Scholar
• Kinney WK, Perkins RB, Sawaya GF. Equal management of equal risks: what should be used as the standard for cervical cancer prevention? J Low Genit Tract Dis. 2018;22(3):237–41. doi:10.1097/LGT.0000000000000402.
   PubMed Web of Science ®Google Scholar
• IARC Working group. IARC handbooks of cancer prevention: cervix cancer screening. Vol. 10. Lyon (France): IARC Press; 2005. Available at http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervix-Cancer-Screening-2005
   Google Scholar
• European Commission. European guidelines for quality assurance in cervical cancer screening. In: editors, Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, et al.Luxembourg: European Union; 2015. Available at https://publications.europa.eu/en/publication-detail/-/publication/a41a4c40-0626-4556-af5b-2619dd1d5ddc
   Google Scholar
• Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(7):687–705. doi:10.1001/jama.2018.10400.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2018;66(3):339–45. doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;7(8):e015867. doi:10.1136/bmjopen-2017-015867.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–138. doi:10.1016/j.vaccine.2012.04.108.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh P, Ferreccio C, Hieu NT, Matos E, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991–98. doi:10.1016/S0140-6736(05)67069-9.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–59. doi:10.1016/S1473-3099(07)70158-5.
   PubMed Web of Science ®Google Scholar
• Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1–2):224–31. doi:10.1016/j.virol.2013.07.015.
   PubMed Web of Science ®Google Scholar
• Karolinska Institutet. International Human Papillomavirus (HPV) Reference Center. [Accessed September 16, 2018]. www.hpvcenter.se
   Google Scholar
• Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553–60. doi:10.1158/1055-9965.EPI-12-1406.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478–88. doi:10.1093/jnci/djq356.
   PubMedGoogle Scholar
• Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. doi:10.1136/bmj.a1754.
   PubMed Web of Science ®Google Scholar
• IARC Working Group. IARC Monographs - 100B: human Papillomaviruses. Lyon (France): WHO Press: International agency for research on cancer; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf.
   Google Scholar
• Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–22. doi:10.1016/S1470-2045(09)70096-8.
   PubMed Web of Science ®Google Scholar
• Pedersen K, Burger EA, Nygard M, Kristiansen IS, Kim JJ. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018;91:68–75. doi:10.1016/j.ejca.2017.12.018.
   PubMed Web of Science ®Google Scholar
• Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, et al. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. Hum Vaccin Immunother. 2018;14(7):1800–06. doi:10.1080/21645515.2018.1450125.
   PubMed Web of Science ®Google Scholar
• Nygard M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw K-L, Dasbach EJ, Kjær SK, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One. 2014;9(2):e88323. doi:10.1371/journal.pone.0088323.
   PubMed Web of Science ®Google Scholar
• Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130–35. doi:10.1097/OLQ.0b013e31827bd66b.
   PubMed Web of Science ®Google Scholar
• Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460. doi:10.1093/jnci/djt460.
   PubMed Web of Science ®Google Scholar
• Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469–74. doi:10.1093/jnci/djt032.
   PubMedGoogle Scholar
• Feiring B, Laake I, Bakken IJ, Greve-Isdahl M, Wyller VB, Håberg SE, Magnus P, Trogstad L. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway. Vaccine. 2017;35(33):4203–12. doi:10.1016/j.vaccine.2017.06.031.
   PubMed Web of Science ®Google Scholar
• Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111(5):965–69. doi:10.1038/bjc.2014.362.
   PubMed Web of Science ®Google Scholar
• Elfstrom KM, Sparen P, Olausson P, Almstedt P, Strander B, Dillner J. Registry-based assessment of the status of cervical screening in Sweden. Journal of Medical Screening. 2016;23(4):217–26. doi:10.1177/0969141316632023.
   PubMed Web of Science ®Google Scholar
• Solomon D, Nayar R. The Bethesda System for reporting cervical cytology. Second. New-York, USA: Springer-Verlag New-York, Inc.; 2004.
   Google Scholar
• Soderlund-Strand A, Eklund C, Kemetli L, Grillner L, Törnberg S, Dillner J, Dillner L. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol. 2011;205(2):145e1–16. doi:10.1016/j.ajog.2011.03.056.
   Web of Science ®Google Scholar
• Eliasen M, Kaer SK, Munk C, Nygård M, Sparén P, Tryggvadottir L, Liaw K-L, Grønbæk M. The relationship between age at drinking onset and subsequent binge drinking among women. Eur J Public Health. 2009;19(4):378–2. doi:10.1093/eurpub/ckp023.
   PubMed Web of Science ®Google Scholar
• Hansen BT, Kjaer SK, Munk C, Tryggvadottir L, Sparén P, Hagerup-Jenssen M, Liaw K-L, Nygård M. Early smoking initiation, sexual behavior and reproductive health - a large population-based study of Nordic women. Prev Med. 2010;51(1):68–72. doi:10.1016/j.ypmed.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Jensen KE, Munk C, Sparen P, Tryggvadottir L, Liaw KL, Dasbach E, NYGÅRD M, KJAER SK. Women’s sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand. 2011;90(5):459–67. doi:10.1111/j.1600-0412.2010.01066.x.
   PubMed Web of Science ®Google Scholar
• Olesen TB, Jensen KE, Nygard M, Tryggvadottir L, Sparén P, Hansen BT, Liaw K-L, Kjaer SK. Young age at first intercourse and risk-taking behaviours–a study of nearly 65 000 women in four Nordic countries. Eur J Public Health. 2012;22(2):220–24. doi:10.1093/eurpub/ckr055.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2012.
   Google Scholar
• Lumley T. Complex surveys: a guide to analysis using R. Hoboken (NJ): Wiley & Sons; 2010. Available at https://onlinelibrary.wiley.com/doi/book/10.1002/9780470580066
   Google Scholar
• Korn EL, Graubard BI. Confidence intervals for proportions with small expected number of positive counts estimated from survey data. Surv Methodol. 1998;24:193–201.
   Google Scholar
• Lewandowski GS, Vaccarello L, Copeland LJ. Surgical issues in the management of carcinoma of the cervix in pregnancy. Surg Clin North Am. 1995;75(1):89–100. doi:10.1016/S0039-6109(16)46536-9.
   PubMed Web of Science ®Google Scholar
• Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M. The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020;38(6):1345–51. doi:10.1016/j.vaccine.2019.12.016.
   PubMed Web of Science ®Google Scholar
• Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C. HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system. BMC Infect Dis. 2014;14(1):413. doi:10.1186/1471-2334-14-413.
   PubMedGoogle Scholar
• Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. doi:10.1086/657321.
   PubMed Web of Science ®Google Scholar
• von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;1:22–31. doi:10.1016/j.pvr.2015.06.006.
   Web of Science ®Google Scholar
• Hashim D, Engesaeter B, Baadstrand Skare G, Castle PE, Bjørge T, Tropé A, Nygård M. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br J Cancer. 2020;122(11):1715–23. doi:10.1038/s41416-020-0790-1.
   PubMed Web of Science ®Google Scholar
• Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay. J Korean Med Sci. 2012;27(9):1091–97. doi:10.3346/jkms.2012.27.9.1091.
   PubMed Web of Science ®Google Scholar
• Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung T-H, Wong MCS, To K-F, Ng H-K, et al. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer. 2009;125(7):1671–77. doi:10.1002/ijc.24495.
   PubMed Web of Science ®Google Scholar
• Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–89. doi:10.1016/S1473-3099(12)70187-1.
   PubMed Web of Science ®Google Scholar
• Hansen BT, Kjaer SK, Arnheim-Dahlstrom L, Liaw KL, Juul KE, Thomsen LT, Frederiksen K, Elfström KM, Munk C, Nygård M, et al. Age at first intercourse, number of partners and sexually transmitted infection prevalence among Danish, Norwegian and Swedish women: estimates and trends from nationally representative cross-sectional surveys of more than 100 000 women. Acta Obstet Gynecol Scand. 2020;99(2):175–85. doi:10.1111/aogs.13732.
   PubMed Web of Science ®Google Scholar
• Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, Garland SM, Chen MY, Fairley CK. Human papillomavirus in young women with chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis. 2015;15(11):1314–23. doi:10.1016/S1473-3099(15)00055-9.
   PubMed Web of Science ®Google Scholar
• Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2017;142(4):709–18. doi:10.1002/ijc.31094.
   PubMed Web of Science ®Google Scholar
• Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525–41. doi:10.1042/CS20050369.
   PubMed Web of Science ®Google Scholar
• Egawa N, Egawa K, Griffin H, Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7(7):3863–90. doi:10.3390/v7072802.
   PubMed Web of Science ®Google Scholar
• Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jerónimo J, Wacholder S, Rodríguez AC, Morales J, Hutchinson M, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26(4):441–46. doi:10.1097/pgp.0b013e31805152ab.
   PubMed Web of Science ®Google Scholar
• Ismail SM, Colclough AB, Dinnen JS, Eakins D, Evans DM, Gradwell E, O’Sullivan JP, Summerell JM, Newcombe RG. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989;298(6675):707–10. doi:10.1136/bmj.298.6675.707.
   PubMed Web of Science ®Google Scholar
• Robertson AJ, Anderson JM, Beck JS, Burnett RA, Howatson SR, Lee FD, Lessells AM, McLaren KM, Moss SM, Simpson JG, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 1989;42(3):231–38. doi:10.1136/jcp.42.3.231.
   PubMed Web of Science ®Google Scholar
• Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Jama. 2001;285(11):1500–05. doi:10.1001/jama.285.11.1500.
   PubMed Web of Science ®Google Scholar
• Skare G, Lönnberg S, Bjorge T, Trope A. Masseundersøkelsen mot livmorhalskreft. Årsrapport 2015: Kreftregisteret. Institutt for populasjonsbasert kreftforskning. Oslo, Norway: Kreftregisteret; 2016.
   Google Scholar
• Dillner J, Nygard M, Munk C, Hortlund M, Hansen BT, Lagheden C, Liaw K-L, Kjaer SK. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018;36(26):3820–29. doi:10.1016/j.vaccine.2018.05.019.
   PubMed Web of Science ®Google Scholar